Seattle Children's-Authored Abstracts | American Society of Hematology 2024 Annual Meeting
Published
Scientists and physician-researchers from Seattle Children’s Research Institute contributed to 16 scientific abstracts being presented at the American Society of Hematology 2024 Annual Meeting:
Myron Evans II, PhD
Shan Lin, PhD
Mignon Loh, MD
- Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731
- Affinity-Tuned T-Cell Engager for Dual Targeting of B-Myeloid Mixed-Phenotype Acute Leukemia (B-MPAL)
- Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma
- Prognostic Impact of t(1;19) in Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Treated on Contemporary Children’s Oncology Group (COG) Protocols
- TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL
- EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin
- Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL
- Examining Disparities By Race, Ethnicity, and Socioeconomic Factors in Children and Young Adults with Relapsed Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
- Diagnosing and Staging Central Nervous System Involvement in Pediatric ALL: A Global Survey on Its Heterogeneity
- Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
- Additional Induction Intrathecal Cytarabine for Patients with CNS2 Disease at Diagnosis Is Not Beneficial for Patients with B-ALL Treated on Children's Oncology Group Protocols AALL0932 and AALL1131
Shannon Oda, PhD
- Developing Novel Cell Therapy Strategies to Convert Macrophage Programming and Induce Synergistic, Multicellular Immunity Against AML
- Engineering Synergistic Adoptive Cell Therapies for Enhanced Treatment of Acute Myeloid Leukemia
Jim Olson, MD, PhD
Rachel Rau, MD
- Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731
- Prognostic Impact of t(1;19) in Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Treated on Contemporary Children’s Oncology Group (COG) Protocols
- TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL
- Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages
Related Categories
Publication Q&A: A Comprehensive Assessment of Associations Between Prenatal Phthalate Exposure and the Placental Transcriptomic Landscape
Published
New research from Drs. Alison Paquette, Sheela Sathyanarayana and Drew Day shows relationships between exposure to certain chemicals called phthalates during pregnancy and the placenta, which may impact fetal development and infant health.
Publication Q&A: Adaptations in Hippo-Yap Signaling and Myofibroblast Fate Underlie Scar-Free Ear Appendage Wound Healing in Spiny Mice
Published
Researchers from the Majesky Lab and Millen Lab recently published a paper reporting the first cellular and molecular mechanisms contributing to tissue regenerative wound healing properties in Acomys.
Seattle Children’s Research Division: Celebrating 15 Years of Innovation
Published
Key Seattle Children’s immunology research findings highlighted at the American Society of Gene and Cell Therapy’s 2025 meeting.